Q32 Bio (QTTB) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Q32 Bio (NASDAQ: QTTB) in the last few weeks:

• 5/18/2026 – Q32 Bio is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 5/18/2026 – Q32 Bio was downgraded by Zacks Research from “strong-buy” to “hold”.
• 5/11/2026 – Q32 Bio was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/5/2026 – Q32 Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $13.00 price target on the stock.

Insider Buying and Selling

In related news, CEO Jodie Pope Morrison sold 9,896 shares of Q32 Bio stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $44,630.96. Following the sale, the chief executive officer directly owned 89,104 shares in the company, valued at $401,859.04. This trade represents a 10.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 16,706 shares of company stock worth $75,344. 40.00% of the stock is owned by company insiders.

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.